GC MG
Patients (No) 83 89
Age    
Mean 61.1 69.3
SD (s) 11.8 15.4
Median 62 71
Range (30-86) (24-97)
Primary Tumor site    
Nasopharynx 9 (11%) 12(13%)
Oral cavity 26(31%) 21(24%)
Salivary glands 2(2%) 2(2%)
Oropharynx 9 (11%) 9 (10%)
Nasal cavity and paranasal sinuses 4(5%) 5(6%)
Hypopharynx 1(1%) 1(1%)
Larynx 19(23%) 28(32%)
Thyroid 5(6%) 1(1%)
Ear 5(6%) 3(3%)
Cervical esophagus 0(0%) 5(6%)
Unknown primary tumour (UPT) 3(4%) 2(2%)
Hystologic type    
Squamous Carcinoma 43(52%) 37(42%)
Epidermoid Carcinoma 29(35%) 22(25%)
Adenocarcinoma 3(4%) 5(5%)
Mucoepidermoid Carcinoma 2(2%) 0
Spinocellular Carcinoma 1(1%) 3(3%)
Hodgkin lymphoma 0
0
0
2(2%)
NHL 3(3%)
Melanoma 2(2%)
Ca papillary 3(4%) 2(2%)
Ca follicular 2(2%) 0
Undifferentiated carcinoma 0 13(15%)
Chemotherapy    
No 27(33%) 62(70%)
pre-RT 28(34%) 14(16%)
concomitant 19(23%) 2(2%)
pre-RT+concomitant 9 (11%) 11(12%)
Radiotherapy    
T (only) 9 (11%) 35(39%)
T + N 64(77%) 47(53%)
N (only) 10(12%) 8(9%)
Table 1: Characteristics of patients